Table 2.
Nomenclature* | Identity† | Mda type‡ |
---|---|---|
mda-E-28, E-34, E-38, E-41, E-45, E-49, E-50 | Fibronectin | Type IV |
mda-E-31 | 2′-5′ oligoadenylate synthetase | Type I |
mda-E-32, E-57, E-58 | LIF | Type II |
mda-E-35 | Transporter 1, ABC | Type I |
mda-E-36, E-42, E-52 | HLA-B | Type I |
mda-E-39 | KIAA0180 | Type II |
mda-E-40 | Vimentin | Type I |
mda-E-44 | Tumor necrosis factor-α | Type II |
mda-E-46, E-55 | Calcium-activated potassium channel | Type IV |
mda-E-47 | Ninjurin 1 | Type IV |
mda-E-51 | HMG-Y protein isoform | Type I |
mda-E-54 | Proteasome 26S subunit | Type IV |
mda-E-61 | Human GADD34 | Type II |
mda-E-68 | mda-6 (p21, Waf1, CIP1, SDI1) | Type IV |
mda-E-43, E-63, E-64 | Novel | Type I |
Clones are designated as melanoma differentiation-associated (mda) and the E designation refers to the fact that the restriction enzyme EcoRII was used for isolation by the RaSH approach.
Sequences were searched against various DNA databases to determine sequence identities. Novel, no similar sequence reported in current DNA databases.
Type I mda gene, inducible by IFN-β and IFN-β + MEZ; Type II mda gene, inducible by MEZ and IFN-β + MEZ; Type III mda gene, inducible by IFN-β, MEZ and IFN-β + MEZ; Type IV mda gene, inducible predominantly by IFN-β + MEZ.